Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 4/2008

01.12.2008

Imaging matrix metalloproteinases in cancer

verfasst von: Randy L. Scherer, J. Oliver McIntyre, Lynn M. Matrisian

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Early detection of both primary tumors and metastatic disease remains a major challenge in the diagnosis and staging of cancer. The recognition of the role of MMPs in both the growth and metastasis of tumors has guided the development not only of therapeutic strategies utilizing synthetic, small-molecule MMP inhibitors (MMPIs), but has also catalyzed methods to detect and image tumors in vivo by means of tumor-associated proteolytic activity. These imaging approaches target MMPs involved in cancer progression via contrast agents linked to MMPIs or to MMP selective and specific substrates with sensitivity enhanced by amplification during enzymatic processing. This review draws attention to a variety of strategies utilized to image MMP activity in vivo.
Literatur
1.
Woessner, J. F., & Nagase, H. (2000). Matrix metalloproteinases and TIMPs. New York: Oxford University Press, Inc.CrossRef
2.
Massova, I., Kotra, L. P., Fridman, R., & Mobashery, S. (1998). Matrix metalloproteinases: Structures, evolution, and diversification. FASEB Journal, 12(12), 1075–1095.PubMed
3.
Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology, 17, 463–516.PubMedCrossRef
4.
Nagase, H., Visse, R., & Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 3(69), 562–573.CrossRef
5.
McKerrow, J. H., Bhargava, V., Hansell, E., Huling, S., Kuwahara, T., Matley, M., et al. (2000). A functional proteomics screen of proteases in colorectal carcinoma. Molecular Medicine, 5(6), 450–460.
6.
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000). Matrix metalloproteinases: Biologic activity and clinical implications. Journal of Clinical Oncology, 5(18), 1135–1149.
7.
MacDougall, J. R., Bani, M. R., Lin, Y., Rak, J., & Kerbel, R. S. (1995). The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cell. Cancer Research, 18(55), 4174–4181.
8.
Vaisanen, A., Tuominen, H., Kallioinen, M., & Turpeenniemihujanen, T. (1996). Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. Journal of Pathology, 3(180), 283–289.CrossRef
9.
Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., et al. (1993). Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research, 53, 5365–5369.PubMed
10.
Sternlicht, M. D., & Bergers, G. (2000). Matrix metalloproteinases as emerging targets in anticancer therapy: Status and prospects. Emerging Therapeutic Targets, 4, 609–633.CrossRef
11.
Martin, M. D., & Matrisian, L. M. (2007). The other side of MMPs: Protective roles in tumor progression. Cancer and Metastasis Reviews, 26(3–4), 717–724.PubMedCrossRef
12.
Martin, M. D., & Matrisian, L. M. (2005). Matrix metalloproteinases as prognostic factors for cancer. Clinical Laboratory Investigations, 6(28), 16–18.
13.
Van de Wiele, C., & Oltenfreiter, R. (2006). Imaging probes targeting matrix metalloproteinases. Cancer Biotherapy & Radiopharmaceuticals, 5(21), 409–417.CrossRef
14.
Weissleder, R., & Ntziachristos, V. (2003). Shedding light onto live molecular targets. Nature Medicine, 1(9), 123–128.CrossRef
15.
McIntyre, J. O., Fingleton, B., Wells, K. S., Piston, D. W., Lynch, C. C., Gautam, S., et al. (2004). Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochemical Journal, Pt 3(377), 617–628.
16.
McIntyre, J. O., & Matrisian, L. M. (2003). Molecular imaging of proteolytic activity in cancer. Journal of Cellular Biochemistry, 6(90), 1087–1097.CrossRef
17.
Tsien, R. Y. (2005). Building and breeding molecules to spy on cells and tumors. FEBS Letters, 4(579), 927–932.CrossRef
18.
Weissleder, R., Tung, C. H., Mahmood, U., & Bogdanov Jr., A. (1999). In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nature Biotechnology, 4(17), 375–378.CrossRef
19.
Bremer, C., Tung, C. H., & Weissleder, R. (2001). In vivo molecular target assessment of matrix metalloproteinase inhibition. Nature Medicine, 6(7), 743–748.CrossRef
20.
Shalinsky, D. R., Brekken, J., Zou, H., McDermott, C. D., Forsyth, P., Edwards, D., et al. (1999). Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Annals of the New York Academy of Sciences, 878, 236–270.PubMedCrossRef
21.
Scherer, R., VanSaun, M., McIntyre, J. O., & Matrisian, L. M. (2008). Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon. Molecular Imaging, (in press).
22.
Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., & Tsien, R. Y. (2004). Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proceedings of the National Academy of Sciences of the United States of America, 51(101), 17867–17872.CrossRef
23.
Zheng, G., Chen, J., Stefflova, K., Jarvi, M., Li, H., & Wilson, B. C. (2007). Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proceedings of the National Academy of Sciences of the United States of America, 21(104), 8989–8994.CrossRef
24.
Levin, C. S. (2005). Primer on molecular imaging technology. European Journal of Nuclear Medicine and Molecular Imaging, 32(Suppl 2), S325–S345.PubMedCrossRef
25.
Wigdal, B. B. S., O’Brien, M., Lewis, K., Fan, F., & Wood, K. (2007). A novel bioluminescent platform for p’-requiring proteolytic activity studies. Proceedings of the 5th General Meeting of the International Proteolysis Society, Patras, Greece, p. 108
26.
Kubota, K. (2001). From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology. Annals of Nuclear Medicine, 6(15), 471–486.
27.
Brown, P. D. (1999). Clinical studies with matrix metalloproteinase inhibitors. APMIS, 1(107), 174–180.
28.
Zheng, Q. H., Fei, X., Liu, X., Wang, J. Q., Bin, S. H., Mock, B. H., et al. (2002). Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nuclear Medicine and Biology, 7(29), 761–770.CrossRef
29.
Fei, X., Zheng, Q. H., Liu, X., Wang, J. Q., Sun, H. B., Mock, B. H., et al. (2003). Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents. Bioorganic & Medicinal Chemistry Letters, 13(13), 2217–2222.CrossRef
30.
Zheng, Q. H., Fei, X., DeGrado, T. R., Wang, J. Q., Stone, K. L., Martinez, T. D., et al. (2003). Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester. Nuclear Medicine and Biology, 7(30), 753–760.CrossRef
31.
Furumoto, S., Takashima, K., Kubota, K., Ido, T., Iwata, R., & Fukuda, H. (2003). Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nuclear Medicine and Biology, 2(30), 119–125.CrossRef
32.
Kopka, K., Breyholz, H. J., Wagner, S., Law, M. P., Riemann, B., Schroer, S., et al. (2004). Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nuclear Medicine and Biology, 2(31), 257–267.CrossRef
33.
Schafers, M., Riemann, B., Kopka, K., Breyholz, H. J., Wagner, S., Schafers, K. P., et al. (2004). Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation, 21(109), 2554–2559.CrossRef
34.
Oltenfreiter, R., Staelens, L., Kersemans, V., Cornelissen, B., Frankenne, F., Foidart, J. M., et al. (2006). Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents. Applied Radiation and Isotopes, 6(64), 677–685.CrossRef
35.
Oltenfreiter, R., Staelens, L., Labied, S., Kersemans, V., Frankenne, F., Noel, A., et al. (2005). Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. Cancer Biotherapy & Radiopharmaceuticals, 6(20), 639–647.
36.
Kulasegaram, R., Giersing, B., Page, C. J., Blower, P. J., Williamson, R. A., Peters, B. S., et al. (2001). In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection. European Journal of Nuclear Medicine, 6(28), 756–761.
37.
Seiki, M. (1999). Membrane-type matrix metalloproteinases. APMIS, 1(107), 137–143.CrossRef
38.
Choyke, P. L., Dwyer, A. J., & Knopp, M. V. (2003). Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 5(17), 509–520.CrossRef
39.
Weinmann, H. J., Laniado, M., & Mutzel, W. (1984). Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiological Chemistry and Physics and Medical NMR, 2(16), 167–172.
40.
Henderson, E., Sykes, J., Drost, D., Weinmann, H. J., Rutt, B. K., & Lee, T. Y. (2000). Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents. Journal of Magnetic Resonance Imaging, 6(12), 991–1003.CrossRef
41.
Ludemann, L., Hamm, B., & Zimmer, C. (2000). Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magnetic Resonance Imaging, 10(18), 1201–1214.CrossRef
42.
Fritz-Hansen, T., Rostrup, E., Larsson, H. B., Sondergaard, L., Ring, P., & Henriksen, O. (1996). Measurement of the arterial concentration of Gd-DTPA using MRI: A step toward quantitative perfusion imaging. Magnetic Resonance in Medicine, 2(36), 225–231.CrossRef
43.
Furman-Haran, E., Margalit, R., Grobgeld, D., & Degani, H. (1996). Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 13(93), 6247–6251.CrossRef
44.
Gore, J. C., Kennan, R. P., & Atlas, S. W. (1996). Magnetic resonance imaging of the brain and spine. Philadelphia: Lippincott-Raven.
45.
Heckl, S., Debus, J., Jenne, J., Pipkorn, R., Waldeck, W., Spring, H., et al. (2002). CNN-Gd(3+) enables cell nucleus molecular imaging of prostate cancer cells: The last 600 nm. Cancer Research, 23(62), 7018–7024.
46.
Wiener, E. C., Konda, S., Shadron, A., Brechbiel, M., & Gansow, O. (1997). Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Investigative Radiology, 12(32), 748–754.CrossRef
47.
Louie, A. Y., Huber, M. M., Ahrens, E. T., Rothbacher, U., Moats, R., Jacobs, R. E., et al. (2000). In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnology, 3(18), 321–325.
48.
Frullano, L., Tejerina, B., & Meade, T. J. (2006). Synthesis and characterization of a doxorubicin-Gd(III) contrast agent conjugate: A new approach toward prodrug–procontrast complexes. Inorganic Chemistry, 21(45), 8489–8491.CrossRef
49.
Lepage, M., Dow, W. C., Melchior, M., You, Y., Fingleton, B., Quarles, C. C., et al. (2007). Non-invasive detection of matrix metalloproteinase activity using a novel MRI contrast agent with a solubility switch. Molecular Imaging, 6(6), 393–403.PubMed
50.
Marten, K., Bremer, C., Khazaie, K., Sameni, M., Sloane, B., Tung, C. H., & Weissleder, R. (2002). Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology, 2(122), 406–414.CrossRef
51.
Funovics, M. A., Alencar, H., Su, H. S., Khazaie, K., Weissleder, R., & Mahmood, U. (2003). Miniaturized multichannel near infrared endoscope for mouse imaging. Molecular Imaging, 4(2), 350–357.CrossRef
52.
Kawada, S., Suzuki, Y., Hinohara, S., Koide, S., Ono, Y., & Ashikaga, H. (2007). Cancer screening with PET: Advantages and limitations. Rinsho Byori, 7(55), 656–667.
53.
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., et al. (2005). Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clinical Cancer Research, 8(11), 2785–2808.CrossRef
54.
Albright, C. F., Graciani, N., Han, W., Yue, E., Stein, R., Lai, Z., et al. (2005). Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity. Molecular Cancer Therapeutics, 5(4), 751–760.CrossRef
55.
Vartak, D. G., & Gemeinhart, R. A. (2007). Matrix metalloproteases: underutilized targets for drug delivery. Journal of Drug Targeting, 1(15), 1–20.CrossRef
56.
Moses, J. E., & Moorhouse, A. D. (2007). The growing applications of click chemistry. Chemical Society Reviews, 8(36), 1249–1262.CrossRef
57.
Cosgrove, D. (2006). Ultrasound contrast agents: an overview. European Journal of Radiology, 3(60), 324–330.CrossRef
58.
Ntziachristos, V., Ripoll, J., Wang, L. V., & Weissleder, R. (2005). Looking and listening to light: the evolution of whole-body photonic imaging. Nature Biotechnology, 3(23), 313–320.CrossRef
Metadaten
Titel
Imaging matrix metalloproteinases in cancer
verfasst von
Randy L. Scherer
J. Oliver McIntyre
Lynn M. Matrisian
Publikationsdatum
01.12.2008
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 4/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-008-9152-9

Weitere Artikel der Ausgabe 4/2008

Cancer and Metastasis Reviews 4/2008 Zur Ausgabe

NON-THEMATIC REVIEW

Caveolin-1 in tumor progression: the good, the bad and the ugly

OriginalPaper

Non-invasive assessment of tumor neovasculature: techniques and clinical applications

OriginalPaper

Tumor detection using folate receptor-targeted imaging agents

OriginalPaper

Imaging hemodynamics

NON-THEMATIC REVIEW

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

OriginalPaper

Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise